Related Experiment Videos

Generation and characterization of polyclonal antibodies specific for human p110 sEGFR

Trace A Christensen1, Jill L Reiter, Andre T Baron

  • 1Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA.

Hybridoma and Hybridomics
|August 8, 2002
PubMed

Insights

Researchers developed specific antibodies for a novel 110 kDa epidermal growth factor receptor (EGFR) isoform, p110 sEGFR. These antibodies distinguish p110 sEGFR from the full-length 170 kDa EGFR, enabling detailed studies of its expression and function.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Cancer Research

Background:

  • The Epidermal Growth Factor Receptor (EGFR) family is crucial for cell growth and transformation.
  • An alternative 3 kb EGFR transcript encodes a 110 kDa isoform, p110 sEGFR, with unique C-terminal amino acids.

Purpose of the Study:

  • To generate and characterize polyclonal antibodies specific to the unique C-terminal sequence of p110 sEGFR.
  • To enable differentiation between p110 sEGFR and full-length 170 kDa EGFR expression.

Main Methods:

  • Polyclonal antisera were raised in rabbits using synthetic peptides from the p110 sEGFR unique sequence.
  • Immune immunoglobulin fractions were affinity-purified using protein G and peptide chromatography.
  • Antibody specificity was confirmed via ELISA, immunoprecipitation, immunoblot analysis, and immunocytochemistry.

Main Results:

  • Generated affinity-purified polyclonal antibodies specifically recognize p110 sEGFR.
  • No cross-reactivity was observed with the full-length 170 kDa EGFR.
  • The antibodies demonstrated high specificity across multiple detection methods.

Conclusions:

  • Newly developed polyclonal antibodies are highly specific for the p110 sEGFR isoform.
  • These antibodies are valuable tools for investigating the expression, localization, and function of p110 sEGFR.
  • The antibodies will facilitate distinguishing p110 sEGFR from p170 EGFR in biological samples.

Related Concept Videos